Oncolytics’ Reolysin Receives FDA Fast Track Designation for Metastatic Breast Cancer
News
The U.S. Food and Drug Administration has granted fast track status to Reolysin for treating metastatic breast cancer, according to its developer, Oncolytics Biotech. Fast track accelerates the review of therapies ... Read more